Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Rheum Dis Clin North Am
; 50(2): 269-279, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38670725
ABSTRACT
The introduction of immune checkpoint inhibitors (ICIs) has changed the landscape of the treatment of cancer. Several immune-related adverse events (irAEs) have now been described such as ICI-inflammatory arthritis (IA), sicca syndrome, polymyalgia rheumatica, myositis, and vasculitis as a consequence of immune activation. The onset of the ICI-IA can vary from after the first infusion of ICIs to a delayed presentation a year or more after ICI initiation. Ultimately, baseline patient and tumor characteristics, the types of immunotherapies used, pre-existing autoimmune diseases, and/or other irAEs, as well as patient preferences will all shape the discussions around ICI-IA management.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Arthritis
/
Immune Checkpoint Inhibitors
Limits:
Humans
Language:
En
Journal:
Rheum Dis Clin North Am
Journal subject:
REUMATOLOGIA
Year:
2024
Type:
Article
Affiliation country:
United States